Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion-Defined Rhabdomyosarcoma.
Saved in:
| Title: | Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion-Defined Rhabdomyosarcoma. |
|---|---|
| Authors: | Bergsma P; Translational Oncology Program, Garvan Institute of Medical Research, Sydney, Australia.; Department of Otorhinolaryngology, Head and Neck Surgery, Cantonal Hospital St. Gallen, St. Gallen, Switzerland., Porazinski S; Translational Oncology Program, Garvan Institute of Medical Research, Sydney, Australia.; Faculty of Medicine, St Vincent's Clinical School, University of NSW Sydney, Randwick, Australia., Istadi A; Translational Oncology Program, Garvan Institute of Medical Research, Sydney, Australia., Chacon-Fajardo D; Translational Oncology Program, Garvan Institute of Medical Research, Sydney, Australia.; Faculty of Medicine, St Vincent's Clinical School, University of NSW Sydney, Randwick, Australia., Mahmood Y; Translational Oncology Program, Garvan Institute of Medical Research, Sydney, Australia., Lombardi S; Translational Oncology Program, Garvan Institute of Medical Research, Sydney, Australia., Schuhmacher D; Translational Oncology Program, Garvan Institute of Medical Research, Sydney, Australia.; Faculty of Medicine, St Vincent's Clinical School, University of NSW Sydney, Randwick, Australia., Barraclough-Franks H; Translational Oncology Program, Garvan Institute of Medical Research, Sydney, Australia., Strbenac D; School of Mathematics and Statistics, The University of Sydney, Sydney, Australia., Dennis CV; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia., Faizi-Sobbi P; Translational Oncology Program, Garvan Institute of Medical Research, Sydney, Australia., Cahill E; Translational Oncology Program, Garvan Institute of Medical Research, Sydney, Australia., Bhadri VA; Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, Australia.; Faculty of Medicine and Health, University of Sydney, Sydney, Australia., De Almeida Silva J; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia., Lum T; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia., Wykes J; Faculty of Medicine and Health, University of Sydney, Sydney, Australia.; Department of Head and Neck Surgery, Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Sydney, Australia., Manzie T; Faculty of Medicine and Health, University of Sydney, Sydney, Australia.; Department of Head and Neck Surgery, Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Sydney, Australia., Palme CE; Faculty of Medicine and Health, University of Sydney, Sydney, Australia.; Department of Head and Neck Surgery, Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Sydney, Australia., Yang JYH; School of Mathematics and Statistics, The University of Sydney, Sydney, Australia., Clark JR; Faculty of Medicine and Health, University of Sydney, Sydney, Australia.; Department of Head and Neck Surgery, Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Sydney, Australia., Gupta R; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia.; Department of Head and Neck Surgery, Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Sydney, Australia., Pajic M; Translational Oncology Program, Garvan Institute of Medical Research, Sydney, Australia.; Faculty of Medicine, St Vincent's Clinical School, University of NSW Sydney, Randwick, Australia. |
| Source: | Molecular cancer therapeutics [Mol Cancer Ther] 2025 Dec 02; Vol. 24 (12), pp. 1989-2004. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 40621788 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion-Defined Rhabdomyosarcoma. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Bergsma+P%22">Bergsma P</searchLink>; Translational Oncology Program, Garvan Institute of Medical Research, Sydney, Australia.; Department of Otorhinolaryngology, Head and Neck Surgery, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.<br /><searchLink fieldCode="AU" term="%22Porazinski+S%22">Porazinski S</searchLink>; Translational Oncology Program, Garvan Institute of Medical Research, Sydney, Australia.; Faculty of Medicine, St Vincent's Clinical School, University of NSW Sydney, Randwick, Australia.<br /><searchLink fieldCode="AU" term="%22Istadi+A%22">Istadi A</searchLink>; Translational Oncology Program, Garvan Institute of Medical Research, Sydney, Australia.<br /><searchLink fieldCode="AU" term="%22Chacon-Fajardo+D%22">Chacon-Fajardo D</searchLink>; Translational Oncology Program, Garvan Institute of Medical Research, Sydney, Australia.; Faculty of Medicine, St Vincent's Clinical School, University of NSW Sydney, Randwick, Australia.<br /><searchLink fieldCode="AU" term="%22Mahmood+Y%22">Mahmood Y</searchLink>; Translational Oncology Program, Garvan Institute of Medical Research, Sydney, Australia.<br /><searchLink fieldCode="AU" term="%22Lombardi+S%22">Lombardi S</searchLink>; Translational Oncology Program, Garvan Institute of Medical Research, Sydney, Australia.<br /><searchLink fieldCode="AU" term="%22Schuhmacher+D%22">Schuhmacher D</searchLink>; Translational Oncology Program, Garvan Institute of Medical Research, Sydney, Australia.; Faculty of Medicine, St Vincent's Clinical School, University of NSW Sydney, Randwick, Australia.<br /><searchLink fieldCode="AU" term="%22Barraclough-Franks+H%22">Barraclough-Franks H</searchLink>; Translational Oncology Program, Garvan Institute of Medical Research, Sydney, Australia.<br /><searchLink fieldCode="AU" term="%22Strbenac+D%22">Strbenac D</searchLink>; School of Mathematics and Statistics, The University of Sydney, Sydney, Australia.<br /><searchLink fieldCode="AU" term="%22Dennis+CV%22">Dennis CV</searchLink>; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia.<br /><searchLink fieldCode="AU" term="%22Faizi-Sobbi+P%22">Faizi-Sobbi P</searchLink>; Translational Oncology Program, Garvan Institute of Medical Research, Sydney, Australia.<br /><searchLink fieldCode="AU" term="%22Cahill+E%22">Cahill E</searchLink>; Translational Oncology Program, Garvan Institute of Medical Research, Sydney, Australia.<br /><searchLink fieldCode="AU" term="%22Bhadri+VA%22">Bhadri VA</searchLink>; Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, Australia.; Faculty of Medicine and Health, University of Sydney, Sydney, Australia.<br /><searchLink fieldCode="AU" term="%22De+Almeida+Silva+J%22">De Almeida Silva J</searchLink>; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia.<br /><searchLink fieldCode="AU" term="%22Lum+T%22">Lum T</searchLink>; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia.<br /><searchLink fieldCode="AU" term="%22Wykes+J%22">Wykes J</searchLink>; Faculty of Medicine and Health, University of Sydney, Sydney, Australia.; Department of Head and Neck Surgery, Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Sydney, Australia.<br /><searchLink fieldCode="AU" term="%22Manzie+T%22">Manzie T</searchLink>; Faculty of Medicine and Health, University of Sydney, Sydney, Australia.; Department of Head and Neck Surgery, Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Sydney, Australia.<br /><searchLink fieldCode="AU" term="%22Palme+CE%22">Palme CE</searchLink>; Faculty of Medicine and Health, University of Sydney, Sydney, Australia.; Department of Head and Neck Surgery, Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Sydney, Australia.<br /><searchLink fieldCode="AU" term="%22Yang+JYH%22">Yang JYH</searchLink>; School of Mathematics and Statistics, The University of Sydney, Sydney, Australia.<br /><searchLink fieldCode="AU" term="%22Clark+JR%22">Clark JR</searchLink>; Faculty of Medicine and Health, University of Sydney, Sydney, Australia.; Department of Head and Neck Surgery, Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Sydney, Australia.<br /><searchLink fieldCode="AU" term="%22Gupta+R%22">Gupta R</searchLink>; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia.; Department of Head and Neck Surgery, Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Sydney, Australia.<br /><searchLink fieldCode="AU" term="%22Pajic+M%22">Pajic M</searchLink>; Translational Oncology Program, Garvan Institute of Medical Research, Sydney, Australia.; Faculty of Medicine, St Vincent's Clinical School, University of NSW Sydney, Randwick, Australia. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101132535%22">Molecular cancer therapeutics</searchLink> [Mol Cancer Ther] 2025 Dec 02; Vol. 24 (12), pp. 1989-2004. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%2C+Inc%22">American Association for Cancer Research, Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101132535 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1538-8514 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215357163%22">15357163 </searchLink><i>NLM ISO Abbreviation: </i>Mol Cancer Ther <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40621788 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1158/1535-7163.MCT-24-0704 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1989 Titles: – TitleFull: Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion-Defined Rhabdomyosarcoma. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Bergsma P – PersonEntity: Name: NameFull: Porazinski S – PersonEntity: Name: NameFull: Istadi A – PersonEntity: Name: NameFull: Chacon-Fajardo D – PersonEntity: Name: NameFull: Mahmood Y – PersonEntity: Name: NameFull: Lombardi S – PersonEntity: Name: NameFull: Schuhmacher D – PersonEntity: Name: NameFull: Barraclough-Franks H – PersonEntity: Name: NameFull: Strbenac D – PersonEntity: Name: NameFull: Dennis CV – PersonEntity: Name: NameFull: Faizi-Sobbi P – PersonEntity: Name: NameFull: Cahill E – PersonEntity: Name: NameFull: Bhadri VA – PersonEntity: Name: NameFull: De Almeida Silva J – PersonEntity: Name: NameFull: Lum T – PersonEntity: Name: NameFull: Wykes J – PersonEntity: Name: NameFull: Manzie T – PersonEntity: Name: NameFull: Palme CE – PersonEntity: Name: NameFull: Yang JYH – PersonEntity: Name: NameFull: Clark JR – PersonEntity: Name: NameFull: Gupta R – PersonEntity: Name: NameFull: Pajic M IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 12 Text: 2025 Dec 02 Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 1538-8514 Numbering: – Type: volume Value: 24 – Type: issue Value: 12 Titles: – TitleFull: Molecular cancer therapeutics Type: main |
| ResultId | 1 |
